Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.58 |
| ▸ | JAK3 | P52333 | 16/20 | 0.52 |
| ▸ | JAK1 | P23458 | 9/20 | 0.52 |
| ▸ | JAK2 | O60674 | 8/20 | 0.52 |
| ▸ | TYK2 | P29597 | 5/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344933 | 1.00 | IRAK4 (0.58) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL12322689 | 1.00 | IRAK4 (0.58) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL2344938 | 1.00 | IRAK4 (0.58) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL12321401 | 0.91 | IRAK4 (0.57) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL2342512 | 0.91 | JAK3 (0.56) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL12321546 | 0.91 | JAK3 (0.56) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL2342508 | 0.91 | JAK3 (0.56) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL12322005 | 0.91 | JAK3 (0.56) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL2342502 | 0.91 | JAK3 (0.56) | IRAK4JAK3JAK1JAK2TYK2 | |
| SCHEMBL12321891 | 0.90 | IRAK4 (0.56) | IRAK4JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | IRAK4 14/4885JAK3 1/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.